Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
RAPIDO trial aimed to reduce distant metastases without compromising locoregional control. Participants were recruited from 54 centers in the Netherlands, Sweden, Spain, Slovenia, Denmark, Norway, and the USA. Median follow-up was 4.6 years. The experimental treatment can be considered as a new standard of treatment in high-risk locally advanced rectal cancer.
